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thioredoxin1, a redoxactive defensive protein that controls
multiple biological functions, in pregnant women. We measured
serum concentrations of thioredoxin1, total hydroperoxides, and
redox potential in 60 pregnant women at the early third trimester:
gestational age of 27–29 weeks. The thioredoxin1 concentration
(mean ± SD) was 90 ± 42 ng/ml. Total hydroperoxides was 471 ±
105 U.CARR (1 U.CARR = 0.08 mg/dl H2O2). Redox potential was
2142 ± 273 µmol/l. The total hydroperoxides: redox potential ratio
(oxidative stress index) was 0.23 ± 0.08. Thioredoxin1, total
hydroperoxides, and oxidative stress index were higher and
redox potential was lower than in blood of healthy adults. Total
hydroperoxides and redox potential were mutually correlated
significantly and negatively. Thioredoxin1 correlated significantly
and negatively and redox potential correlated significantly and
positively with body weight and body mass index. Thioredoxin1
and redox potential correlated significantly and positively with
uric acid and albumin, respectively. Thioredoxin1 and oxidative
stress index correlated significantly and negatively and redox
potential significantly and positively with neonatal birth weight.
These results suggest that high concentrations of thioredoxin1
are linked to high oxidative stress status in pregnant women and
that neonatal birth weight is affected by the maternal oxidative
condition during later pregnancy.
Key Words: later pregnancy, oxidative stress, redox potential, 
thioredoxin, total hydroperoxides
IntroductionAerobic organisms normally generate reactive oxygen-derived
species (ROS) during respiration and metabolism processes.
However, when the generation of ROS exceeds the antioxidant
defense capacity, ROS can damage cellular macromolecules
including proteins, lipids, and nucleic acids.(1) Increased genera-
tion of ROS during growth of the fetal-placental unit is a prominent
feature of pregnancy.(2–6) Further enhancement of oxidative stress
is likely to promote several pregnancy-related disorders including
preeclampsia, fetal growth restriction (FGR), preterm labor, and
low birth weight.(7,8)
Thioredoxin (TRX) is a ubiquitously expressed, multifunctional
protein (12-kDa) that has a redox-active dithiol-disulfide within
the conserved -Cys-Gly-Pro-Cys- sequence.(9) This defensive
protein is induced in response to various stress conditions.(9,10)
Thioredoxin plays a crucial role in ROS detoxification and
transcription factor regulation, each of which is critical to normal
cellular function. Human-TRX-overexpressing transgenic mice
survive longer.(11) and are more resistant to various oxidative
conditions than control mice are.(12–14)
Thioredoxin is expressed in human decidua and trophoblasts,
where it might protect the fertilized egg and placental trophoblasts
from the cytotoxic effects of ROS.(15,16) Histological examination
of the human placenta has revealed that TRX is expressed in
cytotrophoblasts, decidual cells, and stromal cells in the stem
villi.(17) Moreover, examination of human fetal tissues has revealed
that TRX is distributed widely in different tissues and organs.(18)
It is noteworthy that complete deficiency of cytosolic TRX, TRX-1,
results in early embryonic lethality in mice.(19) Overexpression of
TRX-1 reduces oxidative stress in the placenta of transgenic
mice and TRX-1 might promote normal growth and development
in the mouse fetus.(20,21)
These findings suggest that TRX plays a role in growth and
development of the fetal-placental unit in humans. For this study,
we measured serum concentrations of TRX-1 in pregnant women
at the early third trimester of pregnancy. We determined total
hydroperoxides (TH) and redox potential (RP)(22) in the sera for
comparison. We also examined whether the concentrations of
those parameters were associated with subsequent pregnancy and
birth outcomes. This report describes high serum concentrations
of TRX-1 and TH in pregnant women and presents findings
related to maternal and neonatal characteristics.
Materials and Methods
Participants. During August 2011–November 2011, pregnant
women at the early third trimester were asked to participate in this
study. They had visited Perineito Hahatokono Hospital for
Mothers and Children, which is located in Okayama, Japan.
Exclusion criteria were the following: non-Japanese, date of last
menstrual period uncertain, age <20 years or ≥40 years, multiple
pregnancy, smoking or drinking habits, intake of multivitamins,
hypertensive (systolic blood pressure ≥140 mmHg or diastolic
blood pressure ≥90 mmHg) or infectious condition, history of
chronic condition (such as cardiovascular, renal, metabolic,
immunological, and neurological diseases).
In this study, 60 pregnant women were enrolled. Each gave
written informed consent before entering the study. The study,
which was approved by the local ethics committee, was performed
according to the Declaration of Helsinki.
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Clinical and laboratory data. Gestational age (GA) was
estimated based on reported data of the subject’s last menstruation
and ultrasound measurements performed by obstetricians. Body
weight and height, by which the body mass index (BMI) was
calculated, and blood pressure were recorded by trained nurses.
Non-hemolytic venous blood was sampled for measurement of
AST, ALT, LD, creatinine, uric acid, albumin, and glucose using
automated analyzers with commercially available kits. Thiore-
doxin-1 and other oxidative stress biomarkers were measured in
the sera using the methods described below.
Assay of TRX1. Thioredoxin-1 was measured using a sensi-
tive sandwich ELISA system (Redox Bioscience Inc., Kyoto,
Japan) according to the procedure described previously.(10,23)
Two specific mouse monoclonal antibodies to non-overlapping
epitopes of human TRX-1 (ADF 11 and ADF 21) were used.
These antibodies do not cross-react to mitochondrial TRX, TRX-2.
Nakamura and coworkers(10) reported that serum concentrations of
TRX-1 are 10–30 ng/ml in healthy adults, rising to 40–140 ng/ml
in patients presenting with diseases characterized by enhancement
of oxidative stress.(10) In our laboratory, serum TRX-1 concentra-
tions in 13 healthy Japanese adults (female/male: 7/6) aged 32 ± 7
years (18–43 years) determined using this methodology were
20 ± 17 ng/ml (5–53 ng/ml).
Assay of TH and RP. Total hydroperoxides and RP were
measured using the Free Radical Analytical System (Diacron
International, Grosseto, Italy) according to procedures detailed
previously.(22,24) Total hydroperoxides represent the peroxidation
metabolites of proteins, peptides, amino acids, lipids, and fatty
acids. The TH values were measured using the d-ROM (Reactive
Oxygen Metabolites) kit that applies Fenton and Haber–Weiss
reactions, where one U.CARR (unit of TH value) is equivalent to
0.08 mg/dl of H2O2. Reference values reported by the manufac-
turer are 250–300 U.CARR. In healthy Japanese adults, serum TH
values are 275 ± 48 U.CARR for those aged 20–29 years (n = 80)
and 283 ± 50 U.CARR (n = 118) for those aged 30–39 years.(24)
Redox potential indicates the total endogenous (such as
albumin, transferrin, bilirubin, uric acid) and exogenous (such as
ascorbate, carotenes, tocopherols, ubiquinol) antioxidant capacity.
The RP values were measured using the BAP (Biological Anti-
oxidant Potential) kit, which determines the concentration of
antioxidants as agents that reduce iron ion from its ferric (Fe3+) to
ferrous (Fe2+) form. The intensity was estimated photometrically
and the result was expressed as μmol/l. Reference values reported
by the manufacturer are more than 2200 μmol/l. In healthy
Japanese adults, serum RP values are 2546 ± 59 μmol/l for those
aged 20–29 years (n = 80) and 2554 ± 57 μmol/l (n = 118) for
those aged 30–39 years.(24)
The ratio of TH to RP was calculated and designated as
“oxidative stress index (OSI)” because the shift of the oxidant/
antioxidant balance toward the oxidative side represents oxidative
stress.(25) The rough estimation of OSI was around 0.1 in healthy
Japanese adults, as calculated from data reported by Nojima and
coworkers.(24)
Neonatal characteristics at birth. The recorded neonatal
characteristics were the following: mode of delivery, sex, GA,
birth weight (BW) and BW SD score at each GA,(26) Apgar scores,
pH and HCO3− value in umbilical cord blood.
Statistical analysis. Data are presented as mean ± SD and/or
range (minimum–maximum). Differences between groups were
examined using unpaired t test. Correlations between variables
were assessed using Pearson correlation coefficients. Differences
for which p<0.05 were regarded as significant. All statistical
calculations were performed using GraphPad Prism 5.0 (GraphPad
Software Inc., San Diego, CA).
Results
Characteristics of the 60 subjects. The age of the subjects
was 31 ± 5 years (21–39 years). Of the 60 women, 25 women
(42%) were primigravid and 35 (58%) were multigravid. Venous
blood was sampled at the GA of 28 ± 1 weeks (27–29 weeks).
They showed no abnormal results for serum AST, ALT, LD,
creatinine, uric acid, albumin, or glucose. Clinical and laboratory
data of the subjects are presented in Table 1.
Serum concentrations of TRX1, TH, RP, and OSI. Table 2
shows the serum concentrations of TRX-1, TH, RP, and OSI in
the pregnant women at the early third trimester. The TRX-1 was
90 ± 42 ng/ml (11–205 ng/ml). TH was 471 ± 105 U.CARR (193–
708 U.CARR). RP was 2142 ± 273 μmol/l (1430–2601 μmol/l).
OSI was 0.23 ± 0.08 (0.09–0.45). Correlations between the
parameters were the following: r = –0.10, p = 0.43 for TRX-1 vs
TH; r = –0.03, p = 0.85 for TRX-1 vs RP; r = –0.07, p = 0.57 for
TRX-1 vs OSI; r = –0.46, p = 0.0002 for TH vs RP (Fig. 1). A
significant and negative correlation was found between TH and
RP in the subjects.
At the time of blood sampling, 18 pregnant women were taking
oral ritodrine. One woman was taking low-dosage aspirin. No
significant difference was found in the levels of TRX-1, TH, RP,
and OSI between the women taking medication (n = 19) and those
taking no medication (n = 41) (data not shown).
Correlations between oxidative stress biomarkers and
clinical and laboratory data. Correlations between oxidative
stress biomarkers (TRX-1, TH, RP, OSI) and clinical data (age,
body weight, height, BMI, blood pressures) were assessed. Statis-
tical significance was found only for TRX-1 vs BW (r = −0.27,
p = 0.036), TRX-1 vs BMI (r = −0.26, p = 0.041), RP vs BW
(r = 0.33, p = 0.010), and RP vs BMI (r = 0.36, p = 0.005). The
respective correlations between oxidative stress biomarkers and
biochemistry values (AST, ALT, LD, creatinine, uric acid,
albumin, glucose) were also assessed. Statistical significance was
found only for TRX-1 vs uric acid (r = 0.34, p = 0.008) and RP
vs albumin (r = 0.29, p = 0.022).
Table 1. Characteristics of 60 pregnant women at the early third
trimester
Data are expressed as mean ± SD and range.
Age (years) 31 ± 5 (21–39)
Gestational age (weeks) 28 ± 1 (27–29)
Weight (kg) 59 ± 9 (46–95)
Height (m) 159 ± 6 (145–173)
Body mass index (kg/m2) 23 ± 3 (18–35)
Systolic blood pressure (mm Hg) 96 ± 9 (72–123)
Diastolic blood pressure (mm Hg) 54 ± 8 (23–71)
AST (IU/l) 15 ± 3 (10–28)
ALT (IU/l) 10 ± 5 (4–27)
LD (IU/l) 167 ± 18 (132–217)
Creatinine (mg/dl) 0.45 ± 0.06 (0.35–0.58)
Uric acid (mg/dl) 3.1 ± 0.6 (1.8–4.9)
Albumin (g/dl) 3.4 ± 0.2 (3.0–3.9)
Glucose (mg/dl) 77 ± 11 (64–137)
Table 2. Serum concentrations of thioredoxin1 and other oxidative
stress biomarkers in 60 pregnant women
Data are expressed as mean ± SD and range. “Oxidative stress index” is
defined as the ratio of total hydroperoxides (U.CARR) to redox potential
(µmol/l). *A significant and negative correlation was found between
total hydroperoxides and redox potential. (r = −0.46, p = 0.0002).
Thioredoxin1 (ng/ml) 90 ± 42 (11–205)
Total hydroperoxides (U.CARR) 471 ± 105 (193–708)*
Redox potential (µmol/l) 2142 ± 273 (1430–2601)*
Oxidative stress index 0.23 ± 0.08 (0.09–0.45)
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Relation with pregnancy outcome. Of the 60 women,
three subsequently developed nonsevere hypertension. No signifi-
cant difference was identifiable in those levels between the
women who developed hypertension (n = 3) and those who did
not (n = 57). The TRX-1 was 79 ± 44 ng/ml and 90 ± 42 ng/ml,
TH was 425 ± 97 U.CARR and 473 ± 105 U.CARR, RP was
2161 ± 251 µmol/l and 2141 ± 276 µmol/l, and OSI was 0.20 ± 0.05
and 0.23 ± 0.08, respectively. None of the 60 women developed
diabetes mellitus or other critical disorder during later pregnancy.
Relation with birth outcome. None of the 60 women gave
birth to infants with congenital anomalies or those requiring
intensive clinical care such as neonatal asphyxia, respiratory
distress syndrome, sepsis, or organ failure. The neonatal charac-
teristics are presented in Table 3. Of the neonates, 56 were born at
term and 4 were born preterm. No neonate had been asphyxiated at
birth. Their Apgar scores and pH and HCO3− values in umbilical
cord blood were not abnormally low. When correlations between
oxidative stress biomarkers and the BW or BW SD score of the
neonates were tested, statistical significance was found for TH vs
BW (r = –0.26, p = 0.046), RP vs BW (r = 0.31, p = 0.018), and
OSI vs BW (r = –0.33, p = 0.010). Fetal growth restriction criteria
are BW less than the tenth percentile of standard values at each
GA.(26) No significant difference was found in those levels
between the FGR group (n = 5) and the non-FGR group (n = 55).
The TRX-1 was 103 ± 37 ng/ml and 88 ± 43 ng/ml, TH was
477 ± 121 U.CARR and 470 ± 104 U.CARR, RP was 2125 ± 219
μmol/l and 2142 ± 279 μmol/l, and OSI was 0.23 ± 0.07 and
0.23 ± 0.08.
Discussion
Pregnancy per se is a state of oxidative stress arising from
increased placental metabolic activity and increased production of
ROS and relatively reduced total antioxidant capacity.(2) Concen-
trations of oxidative stress biomarkers, including blood lipid
peroxides, oxidized LDL, and 8-isoprostane and urinary 8-
hydroxydeoxyguanosine(1) became higher toward the third tri-
mester of pregnancy than in non-pregnant women.(3,4,6) Notably,
serum TH values (using the d-ROM kit) in pregnant women at 27–
31 weeks of gestation were elevated (531 ± 143 U.CARR; range
153–895 U.CARR).(5) Those values showed significant and
positive correlations with body weight and both systolic and
Fig. 1. Correlations between thioredoxn1 and other oxidative stress biomarkers in 60 pregnant women. A significant and negative correlation
was found between thioredoxin1 and redox potential.
Table 3. Neonatal characteristics at birth
Data are expressed as mean ± SD and range.
Mode of delivery vaginal/cesarean = 43/17
Sex female/male = 21/39
Gestational age (weeks) 39 ± 1 (35–41)
term/preterm = 56/4
Weight (g) 3011 ± 381 (2214–4198)
Weight (SD score) 0.02 ± 0.91 (−2.35–2.38)
Apgar score (1 min) 9.0 ± 0.2 (8–10)
Apgar score (5 min) 9.9 ± 0.3 (9–10)
pH in umbilical cord blood 7.34 ± 0.05 (7.20–7.49)
HCO3− in umbilical cord blood 24 ± 2 (20–29)
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diastolic blood pressures. Regarding antioxidants, erythrocyte
activities of glutathione peroxidase and superoxide dismutase
increased toward the third trimester of pregnancy.(6) In contrast,
the RP values determined by the ferric reducing ability of plasma
test, which exploits the same chemical principle of the BAP kit,
were lower in pregnant women than in non-pregnant women.(6)
In addition, the serum RP values determined using 2,2'-azino-di-
(3-ethylbenzthiazoline sulfonate) were reported to decrease
gradually as pregnancy advances.(4) Collectively, these results
indicate that the total antioxidant capacity in plasma or serum is
not enhanced in spite of the presence of excessive ROS during
later pregnancy.
Only one study has measured serum TRX-1 concentrations in
pregnant women. Kuroda and coworkers(27) reported that serum
TRX-1 concentrations are elevated during pregnancy. The TRX-1
concentrations were, respectively, 57 ± 26 ng/ml, 66 ± 25 ng/ml,
and 66 ± 23 ng/ml in the first, second, and third trimesters of
pregnancy, as compared to the non-pregnant control values
(48 ± 26 ng/ml). The physiological increase of TRX-1 concentra-
tions supports the contention that TRX-1 is involved in the main-
tenance of normal pregnancy in humans.(15–18) Our earlier report
described that the TRX-1 concentrations in umbilical cord blood
(127 ± 81 ng/ml) and those in early breast milk (268 ± 149 ng/ml)
are elevated remarkably.(23) These results indicate that the
systemic release of TRX-1 is enhanced in neonates at birth and
that early breast milk is a rich source of this protein.
In this study, we measured serum TRX-1 concentrations in 60
pregnant women at the early third trimester. Results showed that
their TRX-1 concentrations (90 ± 42 ng/ml) were several times
higher than healthy adult values (10–30 ng/ml).(10) The results are
consistent with data presented by Kuroda and coworkers.(27) We
measured the oxidative stress status further in pregnant women
using d-ROM and BAP tests. The TH values were higher, but the
RP values were lower in the pregnant women, as compared to
healthy adult values.(24) Accordingly, the OSI (0.23 ± 0.08) was
about two times higher than the healthy adult level (around 0.1)(25)
The RP values were found to have significant and negative
correlation with the TH values in the subjects, thereby implying
that antioxidant buffering capacity is attenuated as the oxidative
load increases. The results suggest that the high concentrations of
TRX-1 are linked to physiologically high oxidative stress status
and reduced antioxidant capacity in pregnant women, although
the TRX-1 concentrations per se were not correlated directly with
the other oxidative stress markers.
Among the correlations analyzed statistically, TRX-1 and RP
respectively showed significant negative and positive correlations
with each of BW and BMI in these pregnant women. Although the
causal relation remains unclear, these results suggest that systemic
release of TRX-1 and total antioxidant capacity in serum are
related closely to maternal body size. Additionally, it is intriguing
that TRX-1 and RP showed significant and positive correlations
with uric acid and albumin, respectively, in the subjects. Uric
acid is recognized as a marker of oxidative stress. Uric acid func-
tions not only as an antioxidant but also as a pro-oxidant.(28) The
physiological role of uric acid in the fetal-placental unit might
be complex and multifactorial. The BAP kit does not measure
individual antioxidants. It measures the overall effect of many
non-enzymatic antioxidants.(22) Albumin, which is present in high
concentrations in blood, scavenges various strong oxidants. Our
results support the contention that albumin contributes substan-
tially to the RP value determined by the BAP kit.(29)
Enhancement of oxidative stress during pregnancy has emerged
as a likely promoter of preeclampsia, diabetes mellitus, FGR,
and other pregnancy-related disorders.(30–32) Previous histological
examinations revealed that the levels of 4-hydroxynonenal, TRX,
glutaredoxin, and protein disulfide isomerase were increased in
the placenta in preeclampsia than in uncomplicated pregnancy(33)
and that levels of 8-hydroxydeoxyguanosine and TRX were higher
in the placenta in cases of preeclampsia or FGR than in un-
complicated pregnancy during the third trimester.(34) These results
indicate that TRX might be induced adaptively against oxidative
stress in the placenta in preeclampsia or FGR.
In this study, no significant difference was found in the
biomarkers of women who developed hypertension and those
who did not, or between those who developed FGR and those who
did not. We must admit that the subjects with critical complica-
tions were very few. The predictive value of serum TRX-1
(together with TH, RP, OSI) for the development of pregnancy-
related disorders should be evaluated thoroughly in future studies.
Thioredoxin is known to be expressed widely in the human
female reproductive system, including placenta,(15–17) fetus,(18)
ovary,(35) endometrium,(36) and cervix.(37) The increase in TRX
expression occurs preferentially in the functionally active tissues
and cells in this system. Reportedly, TRX plays a role in reproduc-
tion as a component of the “early pregnancy factor”.(38) Target
disruption of the mouse TRX-1 gene results in early embryonic
lethality.(19) Moreover, TRX-1 is likely to be synthesized in high
amounts in breast tissues of lactating women.(23) These findings,
together with our present results, indicate that TRX-1 provides a
unique protective mechanism that allows the maintenance of
redox balance in the female reproductive processes and outcomes.
This study has some limitations that must be addressed in future
research. First, our study involves a small population, with no
direct measurement of fetal or neonatal oxidative stress status.
Second, information about dietary habits of the subjects was not
available. Third, the samples are not representative of pregnant
women in general because the data were of a hospital-based study.
Finally, the study design is limited by its cross-sectional nature. A
longitudinal study is necessary to ascertain the predictive ability of
the parameters for pregnancy and birth outcomes.
In conclusion, this study documents that serum concentrations
of TRX-1, TH, and OSI are higher and RP is lower in pregnant
women at the early third trimester than in healthy adults and that
the TH and RP correlate significantly and negatively. This study
also demonstrates that TRX-1 correlates significantly and nega-
tively and RP correlates significantly and positively with body
weight and body mass index in the pregnant women. Moreover,
TRX-1 and OSI correlate significantly and negatively and RP
correlates significantly and positively with neonatal birth weight.
These results suggest that the high concentrations of TRX-1 are
linked to high oxidative stress status in pregnant women and that
neonatal birth weight is affected by the maternal oxidative condi-
tion during later pregnancy.
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